Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement
British Journal of Anaesthesia · 2026-06 · 136 (6) · 1776-1799
DOI: 10.1016/j.bja.2026.02.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Anaesthesia, 2026-06. Verfasst von Adriana D Oprea und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Yale School of Medicine, New Haven, CT, USA. Electronic address: adriana.oprea@yale.edu. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Perioperative Care. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 125 Literaturangaben.
Abstract (Originalsprache)
The perioperative management of patients using sodium-glucose cotransporter 2 inhibitors (SGLT2is) remains controversial. The US Food and Drug Administration currently recommends stopping SGLT2is for 3-4 days before surgery, irrespective of a diagnosis of diabetes mellitus. Other multisociety recommendations vary significantly in terms of SGLT2i management, perioperative monitoring, and mitigating strategies for euglycaemic diabetic ketoacidosis. This multidisciplinary consensus statement led by the Society for Perioperative Assessment and Quality Improvement (SPAQI) provides updated recommendations based on a modified Delphi process and supported by a systematic review of the literature. The recommendations include a tailored approach to management of SGLT2is perioperatively based on the presence of diabetes mellitus and other comorbidities, surgical and periprocedural dietary considerations, as well as monitoring and prevention strategies for euglycaemic diabetic ketoacidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Yale School of Medicine, New Haven, CT, USA. Electronic address: adriana.oprea@yale.edu.
- Department of Anesthesiology, Duke University, Durham, NC, USA.
- Department of Anesthesiology, Harvard Medical School, Weiner Center for Preoperative Evaluation, Brigham and Women's Hospital, Boston, MA, USA.
- Department of Hospital Medicine, Cleveland Clinic Lerner College of Medicine of CWRU, Cleveland, OH, USA; Outcomes Research Consortium, Houston, TX, USA.
- Department of Anesthesiology, Stony Brook Medicine, Stony Brook, NY, USA.
- Department of Medicine, Division of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA.
Zitieren
APA
Oprea, A. D., Mohamed, B., Hepner, D. L., Auron, M., Richman, D. C., Umpierrez, G. E., Edmonston, D., Ionescu, C., Kumar, M., & Sweitzer, B. (2026). Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement. British Journal of Anaesthesia, 136(6), 1776-1799. https://doi.org/10.1016/j.bja.2026.02.031
Vancouver
Oprea AD, Mohamed B, Hepner DL, Auron M, Richman DC, Umpierrez GE, et al. Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement. British Journal of Anaesthesia. 2026;136(6):1776-1799. doi:10.1016/j.bja.2026.02.031
BibTeX
@article{Oprea2026,
author = {Oprea, Adriana D and Mohamed, Basma and Hepner, David L and Auron, Moises and Richman, Deborah C and Umpierrez, Guillermo E and Edmonston, Daniel and Ionescu, Costin and Kumar, Mandeep and Sweitzer, BobbieJean},
title = {Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement},
journal = {British Journal of Anaesthesia},
year = {2026},
volume = {136},
number = {6},
pages = {1776--1799},
doi = {10.1016/j.bja.2026.02.031}
}
EUVIMED